Today: 1 April 2026
Subscribe
Browse Category

ASX:PME.AX 18 February 2026 - 4 March 2026

Pro Medicus share price drops again as insiders buy — what ASX:PME traders watch next

Pro Medicus share price drops again as insiders buy — what ASX:PME traders watch next

Pro Medicus shares fell 2.35% to A$123.00 Wednesday, extending a 43% drop for 2026 despite the S&P/ASX 200 closing higher. Directors Anthony Glenning and Deena Shiff bought shares on Feb. 13. The company reported half-year revenue of A$124.8 million and statutory profit after tax of A$171.2 million, boosted by a fair-value gain. Pro Medicus declared a 32-cent interim dividend, ex-dividend Feb. 26, payable March 20.
18 February 2026
··

Stock Market Today

  • Apellis Pharmaceuticals (APLS) Surges 135.4% on Biogen Acquisition Announcement
    April 1, 2026, 9:51 AM EDT. Shares of Apellis Pharmaceuticals (APLS) soared 135.4% to $40.23 after Biogen announced a $5.6 billion all-cash acquisition at $41 per share, an 86% premium to Apellis' 90-day average price. The deal includes contingent payments based on sales milestones of Apellis' approved drugs, Empaveli and Syfovre, which generated $689 million in 2025 revenue with expected growth through 2028. Despite an anticipated quarterly loss of $0.38 per share, the agreement signals strong commercial value and long-term growth potential. Apellis holds a Zacks Rank #3 (Hold), with cautious investor outlook due to slight downward revisions in earnings per share estimates. Biotech peer Autolus Therapeutics (AUTL) rose 8.7% but remains under pressure with a Zacks Rank #4 (Sell).
Go toTop